Abstract 5917
Background
The increase in cancer survival and the development of new therapies has produced an increase in the hospital admissions through the Emergency Department (ED). To assess these patients and their outcome, we designed this study.
Methods
The records of patients admitted between July and November 2018 were studied. The following variables were registered: age, gender, comorbidities, type of cancer, stage, type and line of treatment, date of the last treatment, symptoms at admission, hospitalization length and outcome.
Results
170 patients (83 men and 87 women) entered the study. The mean age was 61.4 years. The most frequent diagnoses were: lung (20%), breast (17.1%), colo-rectal (14.7%) and pancreatic (12.4%) cancers. Stages: I – II (15.5%), III (10.6%) and IV (75.9%). Type of therapy: chemotherapy (74.1%), immunotherapy (9.4%), targeted therapy (16.5%) and homone therapy (2.4%). Line of therapy: neo- or adjuvant (18%), first (46.6%), second (18%), third (9.9%) and fourth or subsequent (7.5%). The most frequent symptoms at admission were: fever (31.4%), dyspnoea (14.8%) and pain 14.8%). Thirty seven point six percent of admissions were because of tumour related complications, 34.7% because of toxicity and 27.1% because of non-leukopenic infection. The mean hospitalization length were 10.3 days. From the 170 patients, 32 died in the hospital and 13 within the first month after discharge. Tumour progression was the cause of death in 75% of the cases and the complications of therapy was in 18.2%. Seventy five percent were receiving a third or subsequent line of therapy and 66.5% received chemotherapy in the last month of life.
Conclusions
Despite all patients were managed according the ESMO and NCCN guidelines, there is a necessity to improve the clinical decisions, in order to improve the patients’ quality of life and the uses of hospital resources. The establishment of Clinical Decision Units in the ED, could help to this goal. Or perhaps there is a “missing link” between guidelines and the real clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Manuel Morales González.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5939 - Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
Presenter: Olga Simonova
Session: Poster Display session 1
Resources:
Abstract
2703 - Uveal melanoma cell lines depend on multiple signaling pathways for survival
Presenter: John Park
Session: Poster Display session 1
Resources:
Abstract
4849 - XAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition.
Presenter: Sungchan Jang
Session: Poster Display session 1
Resources:
Abstract
4801 - XAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERa and switching estrogen function
Presenter: Seung-hun Jang
Session: Poster Display session 1
Resources:
Abstract
3416 - Cancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer
Presenter: Hideaki Karasawa
Session: Poster Display session 1
Resources:
Abstract
4273 - Paired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer
Presenter: Jung-jyh Hung
Session: Poster Display session 1
Resources:
Abstract
4241 - LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin
Presenter: Xin Guo
Session: Poster Display session 1
Resources:
Abstract
5388 - GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
5208 - Characterisation of growth hormone signal transduction in primary melanoma cell lines
Presenter: Karla Sousa
Session: Poster Display session 1
Resources:
Abstract
3156 - LAPTM5 protein can regulate TGF-β mediated MAPK and Smad signaling pathways in ovarian cancer cell
Presenter: Yan Gao
Session: Poster Display session 1
Resources:
Abstract